Insmed reported $23.61B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
BioMarin Pharmaceutical USD 11.99B 575M Feb/2026
Cytokinetics USD 8.06B 1.49B Feb/2026
DBV Technologies USD 274M 17M Sep/2025
Gilead Sciences USD 183.59B 31.31B Feb/2026
Heron Therapeutics USD 145M 6M Sep/2023
Insmed USD 23.91B 13.21B Feb/2026
Novartis USD 303.91B 57.84B Feb/2026
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sarepta Therapeutics USD 2.02B 336M Sep/2025
Ultragenyx Pharmaceutical USD 1.94B 284M Feb/2026
Vertex Pharmaceuticals USD 120.12B 5.09B Feb/2026